Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Understand the compelling reasons to get a no annual fee travel card. Enjoy perks without the extra charges.
26,540 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Mizuho raises Dell's price target to $300 on expected durable demand from agentic AI servers, while UBS nudges valuat...
The battle over who controls listing access is intensifying as AI powered search and private inventories reshape the ...
A lone IBIT block trade worth about $1.26 billion crossed the tape at $43.16 per share, yet the ETF barely budged. Bi...
Three months after the Hormuz disruption, oil prices remain subdued. Record U.S. exports, a slowdown in Chinese deman...
Bitcoin surged past the $65,000 level Sunday night after news of a diplomatic breakthrough sparked risk-on buying. An...
Duquesne Family Office revealed positions in three AI infrastructure semiconductor firms, signaling a thematic bet on...
A Nasdaq-listed firm disclosed it liquidated its entire Bitcoin position, raising questions about the future of crypt...
XRP is flashing warnings on-chain as sellers keep control, with Open Interest near lows and outflows signaling fading...
AI demand is driving a surge in data-center energy use, and space won’t be a quick fix. This report explains why runn...
A Palm Springs estate once owned by Cary Grant has been listed for $12.7 million, offering collectors and investors a...
Trinity Capital remains a high-yield fixture in venture lending, but a balance of losses, dilution, and rate shifts u...